TheraRadar
Landscape / Oncology
Page updated Jun 3, 2026 · using data updated on Jun 3, 2026

Ovarian Cancer Clinical Trial Landscape

Ovarian cancer is a disease in which malignant cells form in the ovaries. It is a significant concern for women's health, often diagnosed at later stages due to subtle early symptoms.

The clinical trial landscape for ovarian cancer reflects substantial research activity, with 1,360 trials registered since 2008. Currently, 541 trials are actively recruiting, enrolling, or active but not recruiting.

A large proportion of these active trials are in early phases of development, with 263 in Phase 1 and 300 in Phase 2. Phase 3 trials account for 81 active studies, while Phase 4 trials are less common, with only 7 ongoing.

AstraZeneca leads industry sponsorship of active trials with 16, followed by AbbVie with 9, Merck with 5, and CanariaBio Inc. and Regeneron, each with 4 active trials. The concentration of trials in Phase 1 and 2 suggests a strong focus on novel therapeutic approaches and early-stage efficacy testing in this disease area.

Trial activity

542 active / 1,369 total since 2008
Active by phase 83 Ph3 / 159 300 Ph2 / 742 264 Ph1 / 710 7 Ph4 / 21

Competitive Intelligence

This Ovarian Cancer competitive landscape maps 16 companies against 14 mechanisms of action (MOA) across 23 active drug-development programs, including 1 with a confirmed FDA PDUFA date. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Ovarian Cancer, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 16 companies 14 mechanisms 23 programs mapped 4 lowTrust (17%) 1 ⚖ PDUFA-dated ⏰ 2 due ≤6 mo click any cell → asset tearsheet
At a glance

Ovarian Cancer shows 23 programs across 16 companies and 14 mechanisms. The most contested mechanism is PARP (11 programs).

Key findings
  • 67% of PARP programs (10 of 15) are combos with novel agents — class-extension work, not class-validation.
  • Top 3 mechanisms (PARP, Topoisomerase I (topotecan), DM4) account for ~30% of programs — class concentration is low.
  • AbbVie runs 7 programs — the deepest pipeline in this view.
  • AstraZeneca has the highest composite score (100) — most-imminent / most-advanced asset weighted higher than program count.
  • 10 hot readouts in next 6 months — most imminent: AbbVie (FR ADC).
  • 22 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
  • 32 single-program mechanisms in the long tail — 5 are Ph2+ first-in-class first-mover bets.
  • 25 NME candidates in the long tail.
  • Most-novel-of-novel: Verastem MAP2K1 (Ph2) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 2 due ≤6 mo⚖ 1 PDUFA-dated

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.
Unverified (lowTrust) cells:
Ph1 Ph2 Ph3 Ph4 ⚠ lowTrust +combo
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
PARP
DM4
FRα ADC
MUC16 × CD3
WEE1 inhibitor
Anti-VEGF (bevacizumab)
FRα-targeted ADC
Topoisomerase I (topotecan)
TROP-2 ADC (next-gen)
EGFR / HER3 bispecific ADC
CD70
Corticosteroid
FAK inhibitor
HER2
AbbVie
AstraZeneca
Genmab
GSK
Merck & Co.
Regeneron
🇨🇳Sichuan Baili
Zentalis
AGO Research
Chongqing Precision
Corcept
🇨🇳InxMed (Shanghai)
Onconic
Daiichi Sankyo
🇨🇳Akeso
EMD Serono Research & Develop…

Phase 3 leaders · most advanced

  1. recruiting Genmab NCT07225270
  2. recruiting Imunon NCT06915025
  3. active AbbVie NCT05445778
  4. active Genmab NCT06619236
  5. active National Cancer Institute (NCI) NCT02839707

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 10 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 51 mapped landscapes — scope-limited, not a global claim.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 51 mapped landscapes
Single-program mechanisms (32) — one program each — earliest-stage, sorted by phase
PhaseMechanismCompanyModalityReadoutTrial
Ph3 HER2 ADC 🌱 Daiichi Sankyo IV 4Q28 NCT06819007
Ph3 PARP inhibitor 🌱 🆕 BeiGene Oral 4Q25 NCT03519230
Ph3 PD-L1 (avelumab) 🌱 EMD Serono Research & Dev… IV ⏰ 3Q26 NCT03815643
Ph3 TPO receptor agonist 🌱 Amgen ⏰ 1Q26 NCT03937154
Ph3 VEGFR 🌱 🆕 Chipscreen IV 4Q24 NCT04921527
Ph2 B7-H3 ADC 🌱 🆕 Daiichi Sankyo 3Q28 NCT06330064
Ph1+Ph2 CDK4/6 🌱 Incyclix Bio Oral 3Q27 NCT05735080
Ph1+Ph2 Claudin 18.2 ADC 🌱 🆕 ⚙️ Heronova ⏰ 3Q26 NCT06873555
Ph2 CTLA-4 (pH-sensitive) 🌱 🆕 OncoC4 IV ⏰ 3Q26 NCT05446298
Ph2 FAK 🌱 🆕 Verastem 4Q25 NCT06682572
Ph2 FR ADC ⚡ 🌱 AbbVie ⏰ 2Q26 NCT06365853
Ph2 GPC3 🌱 🆕 Aston Sci. IV 4Q25 NCT05794659
Ph2 IL-15 superagonist 🌱 🆕 ImmunityBio Cell therapy 2Q27 NCT06710288
Ph2 MAP2K1 ⚡ 🌱 🆕 Verastem 4Q24 NCT04625270
Ph1+Ph2 NAPI2B 🌱 🆕 Tubulis 4Q27 NCT06303505
Ph1+Ph2 PARP1-selective 🌱 AstraZeneca IV 4Q27 NCT05417594
Ph2 PD-1 / VEGF bispecific 🌱 🆕 Akeso ⏰ 2Q26 NCT06560112
Ph2 PD-1 × VEGF bispecific 🌱 🆕 Sunshine Guojian Pharmace… IV 3Q25 NCT06522828
Ph2 PD-L1 / VEGF-A bispecific antibody 🌱 🆕 DualityBio 2Q30 NCT06953089
Ph2 PD-L1 ADC 🌱 🆕 Shanghai Henlius 4Q26 NCT06769152
Ph2 PI3Kβ inhibitor ⚡ 🌱 🆕 Haihe Biopharma 3Q24 NCT05043922
Ph1+Ph2 PVRIG ⚡ 🌱 Compugen 1Q27 NCT06888921
Ph1+Ph2 TNF 🌱 🆕 TILT Biotherapeutics IV 1Q27 NCT05271318
Ph1+Ph2 TP53 ⚡ 🌱 🆕 Jacobio 1Q27 NCT06386146
Ph1 Anti-FR (mAb) 🌱 🆕 Epsilogen ⏰ 3Q26 NCT06547840
Ph1 CLDN6 🌱 🆕 BioNTech Cell & Gene Ther… Cell therapy 3Q28 NCT04503278
Ph1 DDR (ATR/WEE1) 🌱 🆕 AstraZeneca IV 1Q25 NCT02264678
Ph1 GPRC5D ADC 🌱 🆕 ⚙️ Bristol-Myers Squibb 4Q28 NCT06476808
Ph1 Mesothelin (ADC/CAR-T) 🌱 🆕 Verismo 4Q27 NCT05568680
Ph1 MUCIN-16 ADC ⚡ 🌱 🆕 Whitehawk IV 1Q28 NCT07470853
Ph1 PTK7- ADC 🌱 🆕 Whitehawk 4Q28 NCT07444814
Ph1 TCR ⚡ 🌱 🆕 Medigene 4Q27 NCT06748872
Emerging & small-cap sponsors (12) — few programs here — partnering / M&A radar
PhaseMechanismCompanyModalityReadoutTrial
Ph1 PARP Boryung Oral ⏰ 2Q26 NCT07069335
Ph2 PARP CanariaBio Oral 4Q26 NCT05335993
Ph1 PARP Daewoong Oral 1Q27 NCT07371104
Ph1+Ph2 FOLR1 Eisai Oral 3Q30 NCT04300556
Ph3 🇨🇳 Topoisomerase I (topotecan) Hansoh BioMedical R&D Com… IV 1Q27 NCT06855069
Ph3 PARP Imunon IV 4Q32 NCT06915025
Ph3 🇨🇳 HER2 Innovent Biologics (Suzho… IV 4Q27 NCT06834672
Ph3 🇨🇳 HER2 Jiangsu Alphamab Biopharm… IV 4Q26 NCT06751485
Ph3 🇨🇳 Topoisomerase I (topotecan) Jiangsu HengRui Medicine IV 2Q27 NCT06828354
Ph1 Topoisomerase I (topotecan) Nerviano Medical Sciences Oral 2Q27 NCT06930755
Ph3 🇨🇳 Topoisomerase I (topotecan) Suzhou Suncadia Biopharma… IV ⏰ 2Q26 NCT06394492
Ph1+Ph2 FOLR1 Takeda 2Q25 NCT06390995
Unclassified programs (76) — mechanism not captured yet
PhaseMechanismCompanyModalityReadoutTrial
Ph3 INCB123667, Investigator's choice of chemotherapyunclassified Incyte Corporation NCT07214779
Ph3 Sofetabart Mipitecan, Paclitaxel, Topotecanunclassified Eli Lilly and Company NCT07213804
Ph3 avutometinib, Defactinib, Pegylated liposomal doxorubicinunclassified Verastem, Inc. NCT06072781
Ph3 Oregovomab, Paclitaxel, Carboplatinunclassified CanariaBio Inc. NCT04498117
Ph3 olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin…unclassified Genelux Corporation NCT05281471
Ph2+Ph3 NP-G2-044, PLDunclassified Novita Pharmaceuticals, I… NCT07109414
Ph3 AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxelunclassified AstraZeneca NCT07218809
Ph3 Gleolanunclassified NX Development Corp NCT05804370
Ph3 Paclitaxel Lipid Suspension, Conventional paclitaxel or Taxolunclassified Jina Pharmaceuticals Inc. NCT06867562
Ph3 Standard Chemotherapyunclassified Cordgenics, LLC NCT03949283
Ph2+Ph3 Plasmodium immunotherapyunclassified CAS Lamvac (Guangzhou) Bi… NCT05924776
Ph2+Ph3 SHR-1921, carboplatin, carboplatinunclassified Suzhou Suncadia Biopharma… NCT06211023
Ph1+Ph2 Paclitaxel, Carboplatin, Bevacizumabunclassified Imunon NCT05739981
Ph2 Lorigerlimabunclassified MacroGenics NCT06730347
Ph2 INCB123667unclassified Incyte Corporation NCT07023627
Ph1+Ph2 Dual-target CAR-NK cell product, Cyclophosphamideunclassified Beijing Biotech NCT07617753
Ph1+Ph2 INV-6452unclassified Shenzhen Ionova Life Scie… NCT07612891
Ph1+Ph2 Raludotatug Deruxtecan, Carboplatin, Paclitaxelunclassified Merck Sharp & Dohme LLC NCT06843447
Ph1+Ph2 STX-478, Fulvestrant, Ribociclibunclassified Eli Lilly and Company NCT05768139
Ph2 Radspherinunclassified Oncoinvent Solutions AS NCT06504147
Ph1+Ph2 LBL-024 for Injection, Paclitaxel Injectionunclassified Nanjing Leads Biolabs Co.… NCT07042802
Ph1+Ph2 EB-DUALNK, Cyclophosphamide, Fludarabineunclassified Beijing Biotech NCT07589543
Ph1+Ph2 BNT329, CA19-9-targeting monoclonal antibodyunclassified BioNTech SE NCT07186842
Ph1+Ph2 IMA203 Product, IMA203 product- flat dose, IMA203CD8 Productunclassified Immatics US, Inc. NCT03686124
Ph1+Ph2 AZD8421, Camizestrant, Ribociclibunclassified AstraZeneca NCT06188520
Ph2 PF-07104091 monotherapy dose escalation, PF-07104091 + palbocic…unclassified Pfizer NCT04553133
Ph2 B013, Paclitaxel, Placebounclassified Shanghai Jiaolian Drug Re… NCT06434610
Ph1+Ph2 IMNN-001, Carboplatin, Paclitaxelunclassified Imunon NCT03393884
Ph1+Ph2 Elironrasib, Daraxonrasibunclassified Revolution Medicines, Inc. NCT06128551
Ph1+Ph2 THEO-260unclassified Theolytics Limited NCT06618235
Ph1+Ph2 Autologous dual-target CAR-T cells selected from the predefined…unclassified Beijing Biotech NCT07523529
Ph1+Ph2 Oregovomab, Bevacizumab, Paclitaxelunclassified CanariaBio Inc. NCT04938583
Ph2 Oregovomab, Paclitaxel, Carboplatinunclassified CanariaBio Inc. NCT05605535
Ph1+Ph2 Dual-target CAR-NK cell product, Lymphodepleting chemotherapyunclassified Beijing Biotech NCT07480954
Ph2 Ipatasertib, Cobimetinib, Trastuzumab Emtansineunclassified Hoffmann-La Roche NCT04931342
Ph2 CVL237 tabletsunclassified Convalife (Shanghai) Co.,… NCT07446049
Ph2 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HL…unclassified USWM CT, LLC NCT05601752
Ph1+Ph2 BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injec…unclassified BioInvent International AB NCT04752826
Ph1+Ph2 CATALINA-4: A Study to Investigate the Safety and Efficacy of T…unclassified TORL Biotherapeutics, LLC NCT07322094
Ph2 TORL-1-23, TORL-1-23, TORL-1-23unclassified TORL Biotherapeutics, LLC NCT06690775
Ph2 Vigilunclassified Gradalis, Inc. NCT02346747
Ph2 CBX-12unclassified Cybrexa Therapeutics NCT06315491
Ph1+Ph2 SHR-A1811, Carboplatin, Bevacizumabunclassified Suzhou Suncadia Biopharma… NCT06840002
Ph2 2X-121, 2X-121unclassified Allarity Therapeutics NCT03878849
Ph2 IBI363+IBI305unclassified Innovent Biologics (Suzho… NCT07124793
Ph2 Utidelone capsule 75mg/m2/d QD, Utidelone capsule 40mg/m2/d BID…unclassified Beijing Biostar Pharmaceu… NCT07044349
Ph2 Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelo…unclassified Beijing Biostar Pharmaceu… NCT06730581
Ph1+Ph2 BMX-001, Paclitaxel (Taxol)unclassified BioMimetix JV, LLC NCT06620029
Ph1+Ph2 ENB003, Pembrolizumabunclassified ENB Therapeutics, Inc NCT04205227
Ph2 HS-20089unclassified Hansoh BioMedical R&D Com… NCT06014190
Ph1 CTIM-76unclassified Context Therapeutics Inc. NCT06515613
Ph1 BI 3820768unclassified Boehringer Ingelheim NCT07306559
Ph1 MEN2501unclassified Stemline Therapeutics, In… NCT07226427
Ph1 XmAb541, XmAb808unclassified Xencor, Inc. NCT07593092
Ph1 THEO-260unclassified Theolytics Limited NCT07211659
Ph1 CKD-215, D215unclassified Chong Kun Dang Pharmaceut… NCT07532148
Ph1 XMT-1660unclassified Mersana Therapeutics NCT05377996
Ph1 Innocell Autologous Cellular Immunotherapyunclassified PhotonPharma, Inc. NCT06366490
Ph1 IVX037, Sintilimabunclassified ImmVirx Pty Ltd NCT05427487
Ph1 M9466, Tuvusertib, Abiraterone acetateunclassified EMD Serono Research & Dev… NCT06421935
Ph1 XmAb541unclassified Xencor, Inc. NCT06276491
Ph1 WSK-IM02, WSK-IM02unclassified WestVac Biopharma Co., Lt… NCT07462468
Ph1 PLB-002unclassified Primelink BioTherapeitics… NCT07304128
Ph1 IMGN151unclassified AbbVie NCT05527184
Ph1 Cemiplimab, Bevacizumabunclassified Regeneron Pharmaceuticals NCT06469281
Ph1 ABBV-901, Bevacizumabunclassified AbbVie NCT07278336
Ph1 CUSP06unclassified OnCusp Therapeutics, Inc. NCT06234423
Ph1 BL0175unclassified Shanghai Best-Link Biosci… NCT06738966
Ph1 OPB-101unclassified Outpace Bio, Inc. NCT07030907
Ph1 Sovilnesibunclassified Volastra Therapeutics, In… NCT06084416
Ph1 AB-1015unclassified Arsenal Biosciences, Inc. NCT05617755
Ph1 SYN608unclassified Hangzhou SynRx Therapeuti… NCT07088588
Ph1 DS-6000a, DS-6000aunclassified Daiichi Sankyo NCT04707248
Ph1 BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (…unclassified Bio-Path Holdings, Inc. NCT04196257
Ph1 [14C] AZD6738, AZD6738 / ceralasertibunclassified AstraZeneca NCT06754761
Ph1 PRGN-3005 UltraCAR-T cells, PRGN-3005 UltraCAR-T cellsunclassified Precigen, Inc NCT03907527
Drugs in this landscape: Olaparib · Mirvetuximab Soravtansine · Topotecan · Bevacizumab · olaparib · Relacorilant 150 mg once daily (QD)

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
AstraZeneca 16 16 5
AbbVie 10 6 1
Genmab 5 1 2
Merck 4 5 0
CanariaBio Inc. 4 0 1
Regeneron 4 0 0
Xencor, Inc. 3 3 0
Verastem, Inc. 3 1 1
Imunon 3 1 0
Beijing Biotech 3 0 0
USWM CT, LLC 3 0 0
SystImmune Inc. 3 0 0
TORL Biotherapeutics, LLC 3 0 0
Chongqing Precision Biotech Co., Ltd 3 0 0
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 3 0 0

All 15 active Ovarian Cancer sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2024 (117 registered); 2025 saw 117. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (109 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
67
2017
83
2018
82
2019
73
2020
71
2021
104
2022
80
2023
87
2024
117
2025
117
2026
54

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (7)
579
2017 (5)
408
2018 (11)
229
2019 (10)
383
2020 (11)
185
2021 (12)
366
2022 (6)
193
2023 (6)
520
2024 (14)
185
2025 (20)
404
2026 (7)
420

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT07604766 NOT YET RECRUITING
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Genmab n=82
NCT07225270 RECRUITING
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Genmab n=528
NCT06915025 RECRUITING
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon n=500
NCT05445778 ACTIVE NOT RECRUITING
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie n=520
NCT06619236 ACTIVE NOT RECRUITING
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Genmab n=448
NCT02839707 ACTIVE NOT RECRUITING
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI) n=444
NCT07214779 RECRUITING
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Incyte Corporation n=466
NCT01081262 ACTIVE NOT RECRUITING
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
National Cancer Institute (NCI) n=50
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT06824467 RECRUITING
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme LLC n=770
NCT07318558 RECRUITING
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Merck Sharp & Dohme LLC n=900
NCT02446600 ACTIVE NOT RECRUITING
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI) n=579
NCT01167712 ACTIVE NOT RECRUITING
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI) n=692
NCT06819007 RECRUITING
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Daiichi Sankyo n=582
NCT04878094 RECRUITING
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center n=310
NCT07546500 RECRUITING
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc n=420
NCT07544030 RECRUITING
A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
tongweihua n=60
NCT07564141 NOT YET RECRUITING
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Genmab n=688
NCT02502266 ACTIVE NOT RECRUITING
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI) n=582
NCT07545460 NOT YET RECRUITING
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd. n=404
NCT06828354 RECRUITING
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. n=300
NCT06994195 RECRUITING
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd. n=384
NCT04421963 ACTIVE NOT RECRUITING
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
AstraZeneca n=185
NCT05659381 RECRUITING
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
GOG Foundation n=220
NCT05059522 ACTIVE NOT RECRUITING
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer n=68
NCT03772028 ACTIVE NOT RECRUITING
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
The Netherlands Cancer Institute n=538
NCT06072781 RECRUITING
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem, Inc. n=270
NCT04498117 ACTIVE NOT RECRUITING
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio Inc. n=615
NCT06580314 RECRUITING
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology n=880
NCT04095364 ACTIVE NOT RECRUITING
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology n=450
NCT04789694 RECRUITING
Prehabilitation in Gynaecological Cancer Patients
Charles University, Czech Republic n=64
NCT05281471 RECRUITING
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation n=186
NCT03519230 ACTIVE NOT RECRUITING
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
BeiGene n=224
NCT03842982 ACTIVE NOT RECRUITING
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
Centre Oscar Lambret n=362
NCT07472140 RECRUITING
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre n=120
NCT07109414 ACTIVE NOT RECRUITING
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Novita Pharmaceuticals, Inc. n=380
NCT05116189 ACTIVE NOT RECRUITING
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Merck Sharp & Dohme LLC n=643
NCT04575935 RECRUITING
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center n=580
NCT04884360 ACTIVE NOT RECRUITING
D9319C00001- 1L OC Mono Global RCT
AstraZeneca n=366
NCT05827523 RECRUITING
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
National Cancer Center, Korea n=520
NCT05316181 ACTIVE NOT RECRUITING
CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)
National Cancer Center, Korea n=140
NCT04169997 ACTIVE NOT RECRUITING
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Impact Therapeutics, Inc. n=404
NCT07286162 NOT YET RECRUITING
Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer
University Health Network, Toronto n=300
NCT07218809 RECRUITING
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
AstraZeneca n=1,100
NCT06855069 RECRUITING
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Hansoh BioMedical R&D Company n=468
NCT01844986 ACTIVE NOT RECRUITING
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
AstraZeneca n=450
NCT06476184 RECRUITING
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
ARCAGY/ GINECO GROUP n=250
NCT01223248 ACTIVE NOT RECRUITING
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Memorial Sloan Kettering Cancer Center n=220
NCT06817161 RECRUITING
Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:
Centre Francois Baclesse n=116
NCT05804370 RECRUITING
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NX Development Corp n=170
NCT04111978 RECRUITING
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Swiss GO Trial Group n=540
NCT05009082 RECRUITING
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group n=970
NCT01874353 ACTIVE NOT RECRUITING
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
AstraZeneca n=327
NCT05796973 RECRUITING
Measuring Oncological Value of Exercise and Statin
Tampere University Hospital n=240
NCT06954584 RECRUITING
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Tongji Hospital n=424
NCT03522246 ACTIVE NOT RECRUITING
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
pharmaand GmbH n=1,097
NCT06990503 NOT YET RECRUITING
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
Tongji Hospital n=300
NCT06980545 NOT YET RECRUITING
Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer
Assiut University n=50
NCT06791460 RECRUITING
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University n=296
NCT06867562 NOT YET RECRUITING
Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
Jina Pharmaceuticals Inc. n=166
NCT05737303 RECRUITING
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University n=538
NCT02859038 ACTIVE NOT RECRUITING
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
Shanghai Gynecologic Oncology Group n=489
NCT03737643 ACTIVE NOT RECRUITING
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
AstraZeneca n=1,407
NCT06751485 NOT YET RECRUITING
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd n=430
NCT04921527 RECRUITING
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Chipscreen Biosciences, Ltd. n=454
NCT03949283 ACTIVE NOT RECRUITING
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Cordgenics, LLC n=150
NCT06394492 RECRUITING
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=440
NCT06542549 NOT YET RECRUITING
Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
Anhui Provincial Hospital n=100
NCT06539091 NOT YET RECRUITING
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Anhui Provincial Hospital n=51
NCT05924776 NOT YET RECRUITING
Plasmodium Immunotherapy for Advanced Ovarian Cancer
CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. n=30
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT06341907 RECRUITING
Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC
Second Affiliated Hospital of Wenzhou Medical University n=10
NCT06248749 NOT YET RECRUITING
Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer
University of Saskatchewan n=200
NCT06211023 NOT YET RECRUITING
A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=520
NCT04065009 ACTIVE NOT RECRUITING
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
Karolinska Institutet n=220
NCT06188455 NOT YET RECRUITING
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
The First Affiliated Hospital of Xiamen University n=37
NCT02429700 RECRUITING
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Beihua Kong n=132
NCT02429687 RECRUITING
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Beihua Kong n=129
NCT03458221 RECRUITING
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
Gynaecologisch Oncologisch Centrum Zuid n=148
NCT05255471 RECRUITING
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
National Cancer Institute, Naples n=200
NCT04520074 RECRUITING
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Fudan University n=590
NCT04515602 NOT YET RECRUITING
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
Shanghai Gynecologic Oncology Group n=410
NCT04063527 RECRUITING
Phase III Trial of Stage I Ovarian Cancer After Surgery
Japanese Gynecologic Oncology Group n=360
NCT00951496 COMPLETED
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI) n=1,560
NCT03740165 COMPLETED
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Merck Sharp & Dohme LLC n=1,367
NCT04729387 TERMINATED
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis Pharmaceuticals n=358
NCT06007586 COMPLETED
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute n=143
NCT05870748 TERMINATED
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc. n=600
NCT04908787 COMPLETED
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. n=421
NCT05092360 TERMINATED
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Mural Oncology, Inc n=456
NCT04209855 COMPLETED
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
AbbVie n=453
NCT03534453 COMPLETED
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
AstraZeneca n=229
NCT03863860 COMPLETED
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
Jiangsu HengRui Medicine Co., Ltd. n=252
NCT03353831 COMPLETED
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
AGO Research GmbH n=574
NCT02641639 TERMINATED
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Mateon Therapeutics n=70
NCT04421547 TERMINATED
Efficacy of Letrozole in Recurrent Ovarian Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=86
NCT03632798 WITHDRAWN
Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer
Cordgenics, LLC
NCT02891824 COMPLETED
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
ARCAGY/ GINECO GROUP n=614
NCT04227522 COMPLETED
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
North Eastern German Society of Gynaecological Oncology n=42
NCT02470585 TERMINATED
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AbbVie n=1,140
NCT03635489 COMPLETED
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche n=100
NCT03598270 COMPLETED
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
Grupo Español de Investigación en Cáncer de Ovario n=417
NCT04849858 TERMINATED
Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
University of California, Irvine n=13
NCT03402841 COMPLETED
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
AstraZeneca n=279
NCT04296890 COMPLETED
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
ImmunoGen, Inc. n=106
NCT00673335 COMPLETED
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
UNICANCER n=170
NCT04676334 COMPLETED
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
pharmaand GmbH n=34
NCT03940196 COMPLETED
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
NovoCure Ltd. n=540
NCT04460807 TERMINATED
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
Ente Ospedaliero Ospedali Galliera n=23
NCT00716976 COMPLETED
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Children's Oncology Group n=131
NCT01849874 TERMINATED
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Pfizer n=341
NCT04729608 TERMINATED
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Aravive, Inc. n=366
NCT05329545 TERMINATED
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Mersana Therapeutics n=20
NCT01506856 COMPLETED
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Gynecologic Oncology Trial & Investigation Consortium n=655
NCT02580058 COMPLETED
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
Pfizer n=566
NCT02855944 COMPLETED
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH n=349
NCT01968213 COMPLETED
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
pharmaand GmbH n=564
NCT01847274 COMPLETED
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Tesaro, Inc. n=596
NCT03642132 TERMINATED
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
Pfizer n=79
NCT03038100 COMPLETED
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche n=1,301
NCT03398655 COMPLETED
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
Vascular Biogenics Ltd. operating as VBL Therapeutics n=408
NCT00849667 TERMINATED
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Morphotek n=1,100
NCT03106987 COMPLETED
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
AstraZeneca n=220
NCT02477644 COMPLETED
Platine, Avastin and OLAparib in 1st Line
Arcagy Research n=806
NCT02282020 COMPLETED
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
AstraZeneca n=266
NCT00976911 COMPLETED
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Hoffmann-La Roche n=361
NCT04795596 WITHDRAWN
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Menoufia University
NCT03690739 TERMINATED
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
AGO Research GmbH n=9
NCT01379989 COMPLETED
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
Mario Negri Institute for Pharmacological Research n=617
NCT03180307 COMPLETED
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
On Target Laboratories, LLC n=140
NCT03905902 WITHDRAWN
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
SOTIO a.s.
NCT01170650 TERMINATED
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Endocyte n=441
NCT03806049 WITHDRAWN
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
NCT01837251 COMPLETED
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
AGO Research GmbH n=682
NCT00866697 COMPLETED
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Novartis Pharmaceuticals n=940
NCT02490488 COMPLETED
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
AB Science n=248
NCT02631876 COMPLETED
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
ImmunoGen, Inc. n=366
NCT01461850 COMPLETED
Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm
Catholic University of the Sacred Heart n=171
NCT04237090 COMPLETED
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Ciusss de L'Est de l'Île de Montréal n=27
NCT02718417 TERMINATED
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
Pfizer n=998
NCT02421588 COMPLETED
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
PharmaMar n=442
NCT01091636 COMPLETED
Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer
National Cancer Center, Korea n=184
NCT01218490 SUSPENDED
Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer
Institut Cancerologie de l'Ouest n=450
NCT02107066 COMPLETED
Women's Activity and Lifestyle Study in Connecticut
Yale University n=144
NCT01281254 TERMINATED
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
Amgen n=223
NCT01684878 COMPLETED
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
Hoffmann-La Roche n=208
NCT00685256 COMPLETED
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Georgetown University n=245
NCT02311907 COMPLETED
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Alliance for Clinical Trials in Oncology n=195
NCT01493505 TERMINATED
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Amgen n=1,015
NCT01204749 COMPLETED
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Amgen n=919
NCT01704651 COMPLETED
Accelerating Gastrointestinal Recovery
Jamie N. Bakkum-Gamez n=146
NCT01239732 COMPLETED
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
Hoffmann-La Roche n=1,021
NCT02392676 WITHDRAWN
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
AstraZeneca
NCT01840943 TERMINATED
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd. n=32
NCT01196741 COMPLETED
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
University College, London n=107
NCT01492920 WITHDRAWN
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
Gynecologic Oncology Group
NCT00850772 COMPLETED
Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
Queensland Centre for Gynaecological Cancer n=109
NCT00989131 COMPLETED
Study of Paclitaxel in Patients With Ovarian Cancer
Oasmia Pharmaceutical AB n=789
NCT00782145 COMPLETED
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center n=198

Full Ovarian Cancer Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the Ovarian Cancer landscape

How many companies are developing Ovarian Cancer treatments?
16 companies have active or registered Ovarian Cancer programs in TheraRadar's competitive landscape (87 classified trials). The most active are AbbVie, AstraZeneca, and Genmab.
What mechanisms of action are being developed for Ovarian Cancer?
14 distinct mechanisms of action appear across the Ovarian Cancer pipeline, including PARP, DM4, FRα ADC, MUC16 × CD3, and WEE1 inhibitor.
What is the most crowded mechanism in Ovarian Cancer?
PARP is the most contested mechanism in Ovarian Cancer, with 11 programs mapped to it.
Are there upcoming Ovarian Cancer clinical readouts or FDA decisions?
Near-term Ovarian Cancer catalysts include IN10018 in combination (data readout, May '26); Relacorilant 150 mg on (FDA decision, Jul '26); CD70 CAR-T cells (data readout, Dec '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Ovarian Cancer landscape data come from?
Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Ovarian Cancer heatmap free to use?
Yes — viewing and searching the Ovarian Cancer heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

  • In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
  • Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

  1. Healthy-volunteer studies are set aside as non-disease trials.
  2. Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
  3. Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
  4. Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
  5. Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

  1. Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
  2. Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
  3. Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
  4. AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

  • ✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
  • ⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
  • ⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
  • 🌱 First-in-indication — the only program competing on that mechanism within this disease.
  • 🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
  • 🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

  • Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
  • Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
  • Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

  • Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
  • Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
  • MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
  • Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

  • First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
  • NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
  • Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
  • AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
  • Sponsor names are as-filed and may lag current ownership.
  • Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only